CO6270309A2 - Inhibidores tetrahidropiranocromeno de gamma secretasa - Google Patents

Inhibidores tetrahidropiranocromeno de gamma secretasa

Info

Publication number
CO6270309A2
CO6270309A2 CO09149364A CO09149364A CO6270309A2 CO 6270309 A2 CO6270309 A2 CO 6270309A2 CO 09149364 A CO09149364 A CO 09149364A CO 09149364 A CO09149364 A CO 09149364A CO 6270309 A2 CO6270309 A2 CO 6270309A2
Authority
CO
Colombia
Prior art keywords
alkyl
alkylene
substituted
group
groups
Prior art date
Application number
CO09149364A
Other languages
English (en)
Inventor
Wen-Lian Wu
Thomas Bara
Duane Burnett
John W Clader
Martin S Domalski
Yan Jin
Hubert B Josien
Hongmei Li
Xian Liang
Dmitri A Pissarnitski
Thavalakulamgar Sasikumar
Jesse K Wong
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CO6270309A2 publication Critical patent/CO6270309A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

1.- Un compuesto de la formula:o una de sus sales, solvatos o ésteres aceptables para uso farmacéutico, en donde: X se selecciona del grupo que consiste en N y CH2; R1 se selecciona del grupo que consiste en: (1) -alquilen-S(O)2-alquilo(C1-C6), (2) -alquilen-S(O)2-haloalquilo(C1-C6); (3) -alquilen-S(O)2-R6, (4) -alquilen-S(O)2-R8, (5) -alquilen-S(O)2-alquilo(C1-C6) sustituido, (6) -alquilen-(1,1-dioxido de tetrahidrotiofeno), (7) -alquenil-S(O)2-alquilo(C1-C6), y (8) -cicloalquil-S(O)2-alquilo(C1-C6); en donde dicho grupo R1 -alquilen-S(O)2-alquilo(C1-C6) sustituido esta sustituido con uno o mas sustituyentes seleccionados de modo independiente del grupo que consiste en: -OH, halo, -CN, -CF3, -O-alquilo(C1-C6), y -O- (haloalquilo(C1-C6)); R2 se selecciona del grupo que consiste en: H y alquilo; R6 se selecciona del grupo que consiste e. (1) arilo (C6-C14) no sustituido, (2) arilo (C6-C14) sustituido con uno o mas grupos L1A, (3) heteroarilo (C5-C14) no sustituido, (4) heteroarilo (C5-C14) sustituido con uno o mas grupos L1A, (5) heteroarilalquilo(C5-C14) no sustituido, y (5) heteroarilalquilo (C5-C14) sustituido con uno o mas grupos L1A;R8 se selecciona del grupo que consiste en cicloalquilo no sustituido y cicloalquilo sustituido con uno o mas grupos L3 (en donde los ejemplos de dichos grupos cicloalquilo (no sustituido o sustituido) incluyen anillos cicloalquilo C3-C10);cada L3 se selecciona de modo independiente del grupo que consiste en: (1) -CN, (2) =O, (3) -CH2OH, (4) amino, (5) halo, (6) -CH2NH2, (7) -CH2NHalquiIo, (8) -C(O)OH, (9) -alquilen-C(O)NH alquilo (C1 a C6), (10) -alquilen-C(O)N(alquilo (C1 a C6))2 en donde cada alquilo se selecciona de modo independiente, (11) -alquilen-C(O)NH haloalquilo (C1 a C6), y (12) -alquilen-C(O)N(haloalquilo (C1 a C6))2 en donde cada alquilo se selecciona de modo independiente); Ar se selecciona del grupo que consiste en: (1) arilo no sustituido, (2) arilo sustituido con uno o mas grupos L1A, (3) heteroarilo no sustituido, y (4) heteroarilo sustituido con uno o mas grupos L1A; ...
CO09149364A 2007-07-05 2009-12-30 Inhibidores tetrahidropiranocromeno de gamma secretasa CO6270309A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94803307P 2007-07-05 2007-07-05

Publications (1)

Publication Number Publication Date
CO6270309A2 true CO6270309A2 (es) 2011-04-20

Family

ID=39830164

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09149364A CO6270309A2 (es) 2007-07-05 2009-12-30 Inhibidores tetrahidropiranocromeno de gamma secretasa

Country Status (16)

Country Link
US (1) US8664411B2 (es)
EP (1) EP2435416B1 (es)
JP (1) JP5240871B2 (es)
KR (1) KR20100044197A (es)
CN (1) CN101754960A (es)
AR (1) AR067445A1 (es)
AU (1) AU2008275735B2 (es)
BR (1) BRPI0814256A8 (es)
CA (1) CA2691542A1 (es)
CL (1) CL2008001960A1 (es)
CO (1) CO6270309A2 (es)
EC (1) ECSP109845A (es)
PE (1) PE20090435A1 (es)
RU (1) RU2483061C2 (es)
TW (1) TW200908959A (es)
WO (1) WO2009008980A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080095885A (ko) 2006-01-20 2008-10-29 쉐링 코포레이션 벤젠설포닐-크로만, 티오크로만, 테트라하이드로나프탈렌 및 관련된 감마 세크라타제 억제제
WO2009011851A1 (en) 2007-07-17 2009-01-22 Schering Corporation Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors
KR101755737B1 (ko) 2009-09-11 2017-07-07 프로비오드룩 아게 글루타미닐 사이클라제의 억제제로서 헤테로사이클릭 유도체
WO2012040444A2 (en) * 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Treatment of patients with incipient alzheimer's disease
US8933116B2 (en) 2011-04-04 2015-01-13 Merck Sharp & Dohme Corp. Gamma secretase inhibitors
EP2753623A4 (en) * 2011-09-09 2015-01-28 Merck Sharp & Dohme GAMMA SECRETASE INHIBITORS
US9464103B2 (en) 2012-11-29 2016-10-11 Merck Sharp & Dohme Corp. Spirocyclic sulfones as gamma secretase inhibitors
CN104918938B (zh) * 2012-12-20 2017-08-15 詹森药业有限公司 新颖的作为γ分泌酶调节剂的三环3，4‑二氢‑2H‑吡啶并[1，2‑a]吡嗪‑1，6‑二酮衍生物
WO2014111457A1 (en) 2013-01-17 2014-07-24 Janssen Pharmaceutica Nv Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
AU2017356911A1 (en) 2016-11-09 2019-06-20 Bristol-Myers Squibb Company Tricyclic sulfones as ROR gamma modulators
CA3066077A1 (en) 2017-06-07 2018-12-13 Adrx, Inc. Tau aggregation inhibitors
CA3073062A1 (en) 2017-08-18 2019-02-21 Adrx, Inc. Tau aggregation peptide inhibitors
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020006626A (ko) 1999-02-26 2002-01-23 폴락 돈나 엘. 신규한 술폰아미드 화합물 및 그의 용도
FR2827590B1 (fr) * 2001-07-18 2003-10-24 Atuser Transbordeur de liquides alimentaires usages
GB0108591D0 (en) * 2001-04-05 2001-05-23 Merck Sharp & Dohme Therapeutic agents
AU2002324582B9 (en) * 2001-08-03 2006-02-16 Schering Corporation Novel gamma secretase inhibitors
RU2202370C1 (ru) * 2001-12-26 2003-04-20 Эпштейн Олег Ильич Нейропсихотропное лекарственное средство
GB0222833D0 (en) 2002-10-02 2002-11-06 Syngenta Ltd Chemical process
GB0223039D0 (en) * 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
US7410964B2 (en) * 2003-05-16 2008-08-12 Merck Sharp & Dohme Ltd. Cyclohexyl sulphones as gamma-secretase inhibitors
GB0317491D0 (en) * 2003-07-25 2003-08-27 Novartis Ag Organic compounds
DE102005062098A1 (de) * 2005-12-22 2007-06-28 Merck Patent Gmbh Oxaphenanthren-Derivate
KR20080095885A (ko) * 2006-01-20 2008-10-29 쉐링 코포레이션 벤젠설포닐-크로만, 티오크로만, 테트라하이드로나프탈렌 및 관련된 감마 세크라타제 억제제
TW200813054A (en) * 2006-06-02 2008-03-16 Elan Pharm Inc Fused, tricyclic sulfonamide inhibitors of gamma secretase
CA2742486A1 (en) 2008-11-13 2010-05-20 Schering Corporation Gamma secretase modulators

Also Published As

Publication number Publication date
JP5240871B2 (ja) 2013-07-17
AU2008275735B2 (en) 2014-03-27
RU2483061C2 (ru) 2013-05-27
WO2009008980A2 (en) 2009-01-15
BRPI0814256A8 (pt) 2016-02-10
AR067445A1 (es) 2009-10-14
AU2008275735A1 (en) 2009-01-15
KR20100044197A (ko) 2010-04-29
WO2009008980A3 (en) 2009-03-19
CL2008001960A1 (es) 2009-11-27
US8664411B2 (en) 2014-03-04
RU2010103716A (ru) 2011-08-10
EP2435416A2 (en) 2012-04-04
AU2008275735A2 (en) 2010-02-11
EP2435416B1 (en) 2016-03-30
BRPI0814256A2 (pt) 2015-02-03
ECSP109845A (es) 2010-02-26
CA2691542A1 (en) 2009-01-15
TW200908959A (en) 2009-03-01
PE20090435A1 (es) 2009-04-18
CN101754960A (zh) 2010-06-23
JP2010532359A (ja) 2010-10-07
US20110236400A1 (en) 2011-09-29

Similar Documents

Publication Publication Date Title
CO6270309A2 (es) Inhibidores tetrahidropiranocromeno de gamma secretasa
AR052568A1 (es) Derivados de pirazolo -pirimidina como antagonstas de mglur2
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR074021A1 (es) Compuestos heterociclicos fusionados como moduladores del canal ionico
AR080525A1 (es) Un proceso usando reactivos de grignard
AR089774A1 (es) Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
CO6251357A2 (es) Nuevos derivados de acido azabifenilaminobenzoico
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
AR055744A1 (es) Derivados de acido pirimidincarboxilico, su uso para preparar medicamentos y preparacion de dicjhos compuestos
RS52978B (en) FUSIONED AMINO PIRIDIN AS HSP90 INHIBITORS
CY1112006T1 (el) Μακροκυκλικοι αναστολεις του ιου της ηπατιτιδας c
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR048289A1 (es) Eteres de anillos imidazo sulfona sustituidos.
AR096979A1 (es) Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CO6241108A2 (es) Derivados de pirrolopiridina y sus uso como inhibidores de bace
CO6140033A2 (es) Amino-imidazoles y su uso como medicamento para tratar discapacidad coognotiva enfermedad de alzheimer neurodegeneracion y demencia
ES2305452T3 (es) Inhibidores de la catepsina cisteina y proteasa.
AR037816A1 (es) Fenil derivados sustituidos
AR070264A1 (es) Derivados de oxazepinopirimidona heteroarilamida sustituidos
AR061642A1 (es) Derivados de ureas de tropano, su preparacion y su aplicacion en terapeu-tica, procesos de obtencion y composiciones farmaceuticas
AR070136A1 (es) Pirimidil ciclopentanos como inhibidores de la akt proteina quinasa
AR054130A1 (es) Procedimiento para la preparacion de 1-alquil-3-feniluracilos
PE20130155A1 (es) Derivados de ariletinilo
AR099913A1 (es) Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen

Legal Events

Date Code Title Description
FA Application withdrawn